Abrdn Life Sciences Investors (HQL) News Today $15.42 +0.04 (+0.26%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsDividendFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 10:01 PM | marketbeat.com16 Big Dividends We’re Avoiding Like Right NowFew people pay much attention to the management team of a closed-end fund (CEF). But it’s becoming a much more critical factor driving CEF upside (andJuly 21, 2024 | marketbeat.comCornerstone Advisors LLC Sells 462,426 Shares of Abrdn Life Sciences Investors (NYSE:HQL)Cornerstone Advisors LLC trimmed its position in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 93.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 31,914 shares of the company's stock after selling 462,426 sharesJuly 19, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Director Rose Dimartino Acquires 1,000 SharesJuly 18, 2024 | marketbeat.comRose Dimartino Acquires 1,000 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) Director Rose Dimartino acquired 1,000 shares of Abrdn Life Sciences Investors stock in a transaction dated Tuesday, July 16th. The shares were bought at an average cost of $15.53 per share, with a total value of $15,530.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $15,530. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.June 26, 2024 | insidertrades.comSaba Capital Management, L.P. Purchases 13,812 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockJune 15, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Purchases $33,312.00 in StockJune 14, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Buys $33,312.00 in StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 2,400 shares of the stock in a transaction that occurred on Wednesday, June 12th. The stock was acquired at an average cost of $13.88 per share, with a total value of $33,312.00. Following the completion of the purchase, the insider now owns 3,407,612 shares of the company's stock, valued at $47,297,654.56. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.June 12, 2024 | insidertrades.comSaba Capital Management, L.P. Purchases 9,704 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockJune 11, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Purchases $133,041.84 in StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 9,704 shares of Abrdn Life Sciences Investors stock in a transaction that occurred on Monday, June 10th. The stock was bought at an average cost of $13.71 per share, for a total transaction of $133,041.84. Following the purchase, the insider now directly owns 3,403,173 shares in the company, valued at $46,657,501.83. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.June 11, 2024 | insidertrades.comInsider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Buys 9,598 Shares of StockJune 10, 2024 | marketbeat.comInsider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires 9,598 Shares of StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 9,598 shares of Abrdn Life Sciences Investors stock in a transaction on Thursday, June 6th. The shares were bought at an average price of $13.80 per share, for a total transaction of $132,452.40. Following the purchase, the insider now owns 3,389,706 shares of the company's stock, valued at $46,777,942.80. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their sales and purchases with the SEC.June 6, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Purchases 33,357 SharesJune 5, 2024 | marketbeat.comSaba Capital Management, L.P. Buys 33,357 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 33,357 shares of the business's stock in a transaction on Tuesday, June 4th. The shares were bought at an average cost of $13.50 per share, for a total transaction of $450,319.50. Following the completion of the transaction, the insider now directly owns 3,354,025 shares in the company, valued at approximately $45,279,337.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.June 1, 2024 | marketbeat.comShort Interest in Abrdn Life Sciences Investors (NYSE:HQL) Rises By 26.0%Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 73,600 shares, an increase of 26.0% from the April 30th total of 58,400 shares. Based on an average trading volume of 83,200 shares, the short-interest ratio is currently 0.9 days.June 1, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Acquires 8,714 SharesMay 24, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires $17,590.50 in StockMay 23, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Buys 1,303 SharesAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 1,303 shares of the firm's stock in a transaction that occurred on Thursday, May 23rd. The stock was purchased at an average price of $13.50 per share, with a total value of $17,590.50. Following the completion of the purchase, the insider now owns 3,251,883 shares in the company, valued at $43,900,420.50. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.May 20, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Raises Dividend to $0.48 Per ShareAbrdn Life Sciences Investors (NYSE:HQL) declared a quarterly dividend on Thursday, May 9th. Stockholders of record on Thursday, May 23rd will be paid a dividend of 0.48 per share on Friday, June 28th. This represents a $1.92 annualized dividend and a dividend yield of 13.62%. The ex-dividend date is Wednesday, May 22nd. This is a boost from Abrdn Life Sciences Investors's previous quarterly dividend of $0.39.May 19, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Shares Purchased by Cornerstone Advisors LLCCornerstone Advisors LLC raised its position in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 73.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 494,340 shares of the company's stock after purchasing an addMay 18, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires $493,173.45 in StockMay 17, 2024 | marketbeat.comSaba Capital Management, L.P. Purchases 34,755 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 34,755 shares of the business's stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $14.19 per share, with a total value of $493,173.45. Following the completion of the purchase, the insider now directly owns 3,250,580 shares of the company's stock, valued at approximately $46,125,730.20. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.May 15, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Acquires 57,862 SharesMay 14, 2024 | marketbeat.comSaba Capital Management, L.P. Purchases 57,862 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 57,862 shares of the stock in a transaction dated Friday, May 10th. The stock was acquired at an average price of $13.86 per share, for a total transaction of $801,967.32. Following the completion of the transaction, the insider now directly owns 3,215,825 shares of the company's stock, valued at $44,571,334.50. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.May 12, 2024 | uk.investing.comSaba Capital Management buys abrdn Life Sciences shares worth $390kMay 11, 2024 | insidertrades.comSaba Capital Management, L.P. Buys 10,986 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockMay 10, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Purchases 10,986 SharesAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 10,986 shares of the firm's stock in a transaction on Wednesday, May 8th. The stock was purchased at an average cost of $13.70 per share, for a total transaction of $150,508.20. Following the completion of the acquisition, the insider now owns 3,140,590 shares in the company, valued at $43,026,083. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.May 8, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Purchases 10,713 SharesMay 7, 2024 | marketbeat.comInsider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires 10,713 Shares of StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 10,713 shares of Abrdn Life Sciences Investors stock in a transaction dated Monday, May 6th. The shares were bought at an average price of $13.62 per share, with a total value of $145,911.06. Following the completion of the acquisition, the insider now directly owns 3,079,443 shares of the company's stock, valued at $41,942,013.66. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.May 3, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Purchases $353,648.04 in StockMay 2, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Acquires 26,274 SharesAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 26,274 shares of the business's stock in a transaction dated Thursday, May 2nd. The shares were bought at an average price of $13.46 per share, for a total transaction of $353,648.04. Following the completion of the acquisition, the insider now owns 3,068,730 shares in the company, valued at $41,305,105.80. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.May 2, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Buys 16,573 SharesMay 1, 2024 | marketbeat.comInsider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Purchases 16,573 Shares of StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 16,573 shares of the firm's stock in a transaction that occurred on Tuesday, April 30th. The shares were bought at an average price of $13.13 per share, with a total value of $217,603.49. Following the acquisition, the insider now directly owns 3,042,204 shares in the company, valued at $39,944,138.52. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.April 30, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Buys 120,304 SharesApril 30, 2024 | markets.businessinsider.comXlife Sciences AG Reports Strong Portfolio Growth and Strategic Advances in the 2023 Valuation ReportApril 29, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Acquires 120,304 SharesAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 120,304 shares of the stock in a transaction that occurred on Friday, April 26th. The shares were bought at an average price of $13.00 per share, with a total value of $1,563,952.00. Following the completion of the transaction, the insider now owns 3,025,602 shares in the company, valued at $39,332,826. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.April 27, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Acquires 20,529 SharesApril 26, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Saba Capital Management, L.P. Buys 20,529 SharesAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. bought 20,529 shares of the firm's stock in a transaction that occurred on Wednesday, April 24th. The stock was purchased at an average cost of $13.12 per share, with a total value of $269,340.48. Following the completion of the transaction, the insider now owns 2,807,724 shares in the company, valued at $36,837,338.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.April 24, 2024 | marketbeat.comWolverine Asset Management LLC Sells 114,766 Shares of Abrdn Life Sciences Investors (NYSE:HQL)Wolverine Asset Management LLC decreased its holdings in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 35.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 207,392April 24, 2024 | insidertrades.comInsider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires 2,022 Shares of StockApril 23, 2024 | marketbeat.comSaba Capital Management, L.P. Buys 2,022 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. acquired 2,022 shares of the stock in a transaction dated Monday, April 22nd. The shares were bought at an average cost of $12.88 per share, for a total transaction of $26,043.36. Following the acquisition, the insider now owns 2,738,992 shares in the company, valued at approximately $35,278,216.96. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.April 23, 2024 | insidertrades.comAbrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires $1,046,246.40 in StockApril 22, 2024 | marketbeat.comSaba Capital Management, L.P. Purchases 81,738 Shares of Abrdn Life Sciences Investors (NYSE:HQL) StockAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 81,738 shares of the company's stock in a transaction on Thursday, April 18th. The shares were purchased at an average price of $12.80 per share, with a total value of $1,046,246.40. Following the completion of the purchase, the insider now directly owns 2,694,511 shares of the company's stock, valued at $34,489,740.80. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.April 19, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Shares Bought by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC lifted its position in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 30.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 454,154 shares of the company's stock afteApril 11, 2024 | marketbeat.comRaymond James Financial Services Advisors Inc. Has $1.76 Million Position in Abrdn Life Sciences Investors (NYSE:HQL)Raymond James Financial Services Advisors Inc. grew its stake in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 183.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 131,077 sharMarch 21, 2024 | finance.yahoo.comabrdn Healthcare Investors (HQH), abrdn Life Sciences Investors (HQL), abrdn Healthcare Opportunities Fund (THQ), and abrdn World Healthcare Fund (THW) Announce Investment Team UpdateMarch 13, 2024 | marketbeat.comAbrdn Life Sciences Investors (NYSE:HQL) Sees Significant Decrease in Short InterestAbrdn Life Sciences Investors (NYSE:HQL - Get Free Report) was the target of a large decline in short interest during the month of February. As of February 29th, there was short interest totalling 56,000 shares, a decline of 58.0% from the February 14th total of 133,400 shares. Based on an average trading volume of 130,100 shares, the days-to-cover ratio is currently 0.4 days.March 8, 2024 | msn.comSYRA: Takeaways from Life Science Investor Forum PresentationMarch 1, 2024 | bizjournals.comA 2024 life sciences outlook in Boston – and beyondFebruary 27, 2024 | marketbeat.comClough Capital Partners L P Acquires New Stake in Abrdn Life Sciences Investors (NYSE:HQL)Clough Capital Partners L P purchased a new stake in Abrdn Life Sciences Investors (NYSE:HQL - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 130,450 shares of the company'sFebruary 19, 2024 | marketbeat.comQuantedge Capital Pte Ltd Has $1.18 Million Stock Position in Abrdn Life Sciences Investors (NYSE:HQL)Quantedge Capital Pte Ltd grew its holdings in shares of Abrdn Life Sciences Investors (NYSE:HQL - Free Report) by 60.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 94,420 shares of the company's stock afte Get Abrdn Life Sciences Investors News Delivered to You Automatically Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. Email Address “Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event. You can find out what they are by clicking here now. HQL Media Mentions By Week HQL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HQL News Sentiment▼0.930.50▲Average Finance News Sentiment HQL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HQL Articles This Week▼31▲HQL Articles Average Week Get Abrdn Life Sciences Investors News Delivered to You Automatically Sign up to receive the latest news and ratings for HQL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: GAB News Today STEW News Today CET News Today GAM News Today QQQX News Today MUC News Today MFIC News Today HQH News Today MQY News Today SLRC News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:HQL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abrdn Life Sciences Investors Please log in to your account or sign up in order to add this asset to your watchlist. Share Abrdn Life Sciences Investors With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.